Logo image of NTRA

NATERA INC (NTRA) Stock Fundamental Analysis

NASDAQ:NTRA - Nasdaq - US6323071042 - Common Stock - Currency: USD

160.43  -2.93 (-1.79%)

After market: 160.43 0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to NTRA. NTRA was compared to 560 industry peers in the Biotechnology industry. NTRA has a great financial health rating, but its profitability evaluates not so good. NTRA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year NTRA has reported negative net income.
NTRA had a positive operating cash flow in the past year.
NTRA had negative earnings in each of the past 5 years.
In the past 5 years NTRA reported 4 times negative operating cash flow.
NTRA Yearly Net Income VS EBIT VS OCF VS FCFNTRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200M -400M

1.2 Ratios

NTRA has a Return On Assets of -10.95%. This is amongst the best in the industry. NTRA outperforms 83.99% of its industry peers.
NTRA has a Return On Equity of -15.31%. This is amongst the best in the industry. NTRA outperforms 87.19% of its industry peers.
Industry RankSector Rank
ROA -10.95%
ROE -15.31%
ROIC N/A
ROA(3y)-26.97%
ROA(5y)-28.74%
ROE(3y)-50.12%
ROE(5y)-53.96%
ROIC(3y)N/A
ROIC(5y)N/A
NTRA Yearly ROA, ROE, ROICNTRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

NTRA has a better Gross Margin (61.79%) than 79.54% of its industry peers.
NTRA's Gross Margin has improved in the last couple of years.
NTRA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.79%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.09%
GM growth 5Y7.51%
NTRA Yearly Profit, Operating, Gross MarginsNTRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 -60

More info and screens

7

2. Health

2.1 Basic Checks

NTRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
NTRA has more shares outstanding than it did 1 year ago.
NTRA has more shares outstanding than it did 5 years ago.
NTRA has a better debt/assets ratio than last year.
NTRA Yearly Shares OutstandingNTRA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
NTRA Yearly Total Debt VS Total AssetsNTRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

An Altman-Z score of 25.90 indicates that NTRA is not in any danger for bankruptcy at the moment.
The Altman-Z score of NTRA (25.90) is better than 95.73% of its industry peers.
The Debt to FCF ratio of NTRA is 0.94, which is an excellent value as it means it would take NTRA, only 0.94 years of fcf income to pay off all of its debts.
NTRA has a Debt to FCF ratio of 0.94. This is amongst the best in the industry. NTRA outperforms 95.20% of its industry peers.
A Debt/Equity ratio of 0.06 indicates that NTRA is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.06, NTRA is not doing good in the industry: 62.99% of the companies in the same industry are doing better.
Although NTRA does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.94
Altman-Z 25.9
ROIC/WACCN/A
WACC9.76%
NTRA Yearly LT Debt VS Equity VS FCFNTRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

A Current Ratio of 3.87 indicates that NTRA has no problem at all paying its short term obligations.
The Current ratio of NTRA (3.87) is comparable to the rest of the industry.
A Quick Ratio of 3.74 indicates that NTRA has no problem at all paying its short term obligations.
With a Quick ratio value of 3.74, NTRA perfoms like the industry average, outperforming 45.73% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.87
Quick Ratio 3.74
NTRA Yearly Current Assets VS Current LiabilitesNTRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 52.88% over the past year.
Looking at the last year, NTRA shows a very strong growth in Revenue. The Revenue has grown by 51.50%.
NTRA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 41.20% yearly.
EPS 1Y (TTM)52.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.71%
Revenue 1Y (TTM)51.5%
Revenue growth 3Y39.47%
Revenue growth 5Y41.2%
Sales Q2Q%36.46%

3.2 Future

NTRA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.79% yearly.
NTRA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.78% yearly.
EPS Next Y-46.63%
EPS Next 2Y14.74%
EPS Next 3Y28.2%
EPS Next 5Y28.79%
Revenue Next Year20.24%
Revenue Next 2Y18.12%
Revenue Next 3Y17.56%
Revenue Next 5Y14.78%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
NTRA Yearly Revenue VS EstimatesNTRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B
NTRA Yearly EPS VS EstimatesNTRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

NTRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NTRA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NTRA Price Earnings VS Forward Price EarningsNTRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 100 -100 -150

4.2 Price Multiples

NTRA's Price/Free Cash Flow ratio is rather cheap when compared to the industry. NTRA is cheaper than 91.28% of the companies in the same industry.
Industry RankSector Rank
P/FCF 257.15
EV/EBITDA N/A
NTRA Per share dataNTRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A more expensive valuation may be justified as NTRA's earnings are expected to grow with 28.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.74%
EPS Next 3Y28.2%

More info and screens

0

5. Dividend

5.1 Amount

NTRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NATERA INC

NASDAQ:NTRA (7/11/2025, 8:00:02 PM)

After market: 160.43 0 (0%)

160.43

-2.93 (-1.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)07-31 2025-07-31/amc
Inst Owners93.34%
Inst Owner Change0.01%
Ins Owners3.17%
Ins Owner Change0.66%
Market Cap21.91B
Analysts86.92
Price Target204.26 (27.32%)
Short Float %4.74%
Short Ratio4.83
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)10.14%
Min EPS beat(2)-2.77%
Max EPS beat(2)23.06%
EPS beat(4)3
Avg EPS beat(4)33.31%
Min EPS beat(4)-2.77%
Max EPS beat(4)57.31%
EPS beat(8)7
Avg EPS beat(8)23.1%
EPS beat(12)10
Avg EPS beat(12)16.88%
EPS beat(16)11
Avg EPS beat(16)9.64%
Revenue beat(2)2
Avg Revenue beat(2)9.58%
Min Revenue beat(2)8.92%
Max Revenue beat(2)10.25%
Revenue beat(4)4
Avg Revenue beat(4)14.15%
Min Revenue beat(4)8.92%
Max Revenue beat(4)19.28%
Revenue beat(8)8
Avg Revenue beat(8)10.59%
Revenue beat(12)10
Avg Revenue beat(12)7.32%
Revenue beat(16)14
Avg Revenue beat(16)6.54%
PT rev (1m)0.01%
PT rev (3m)1.16%
EPS NQ rev (1m)-0.84%
EPS NQ rev (3m)-8.53%
EPS NY rev (1m)-1.51%
EPS NY rev (3m)-1.1%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)2.43%
Revenue NY rev (1m)0.2%
Revenue NY rev (3m)3.83%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.96
P/FCF 257.15
P/OCF 143.07
P/B 17.67
P/tB 17.67
EV/EBITDA N/A
EPS(TTM)-1.47
EYN/A
EPS(NY)-1.05
Fwd EYN/A
FCF(TTM)0.62
FCFY0.39%
OCF(TTM)1.12
OCFY0.7%
SpS13.41
BVpS9.08
TBVpS9.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.95%
ROE -15.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.79%
FCFM 4.65%
ROA(3y)-26.97%
ROA(5y)-28.74%
ROE(3y)-50.12%
ROE(5y)-53.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.09%
GM growth 5Y7.51%
F-Score6
Asset Turnover1.06
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.94
Debt/EBITDA N/A
Cap/Depr 204.95%
Cap/Sales 3.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.87
Quick Ratio 3.74
Altman-Z 25.9
F-Score6
WACC9.76%
ROIC/WACCN/A
Cap/Depr(3y)232.23%
Cap/Depr(5y)273.02%
Cap/Sales(3y)4.66%
Cap/Sales(5y)5.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.71%
EPS Next Y-46.63%
EPS Next 2Y14.74%
EPS Next 3Y28.2%
EPS Next 5Y28.79%
Revenue 1Y (TTM)51.5%
Revenue growth 3Y39.47%
Revenue growth 5Y41.2%
Sales Q2Q%36.46%
Revenue Next Year20.24%
Revenue Next 2Y18.12%
Revenue Next 3Y17.56%
Revenue Next 5Y14.78%
EBIT growth 1Y40.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-51.38%
EBIT Next 3Y36.04%
EBIT Next 5Y33.74%
FCF growth 1Y120.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y140.82%
OCF growth 3YN/A
OCF growth 5YN/A